MedTrace Logo

Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation

NCT00392431 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2007-03-22

No results posted yet for this study

Summary

Our hypothesis is that episodic amiodarone treatment (i.e. amiodarone treatment 1 month prior until 1 month after cardioversion) is associated with a lower morbidity and a higher quality of life compared to continuous prophylactic amiodarone treatment while atrial fibrillation is still effectively suppressed. The latter means that at the end of the study permanent atrial fibrillation is prevented in comparable percentage of patients (70%) in both treatment strategies. However, this will be accomplished at the cost of a higher number of electrical cardioversions (2-3) in the episodic treatment group compared to the continuous treatment group.

Conditions

  • Persistant Atrial Fibrillation

Interventions

DRUG

amiodarone

Sponsors & Collaborators

  • Netherlands Heart Foundation

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Isabelle C Van Gelder, MD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2007-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392431 on ClinicalTrials.gov